AVXL

$3.27-$0.14 (-4.11%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$316.1M

93M shares

52-week range

$2.26 – $10.64

12% from low

Sector

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Exchange

NASDAQ

Change$-15.73

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$776M	+5297.1%	$-0.33	$-0.33–$-0.33	—	1
2027	$1.2B	+55.9%	$-0.55	$-0.55–$-0.55	—	1
2028	$349M	-71.2%	$2.27	$2.27–$2.27	1.4×	1
2029	$713M	+104.6%	$4.66	$4.66–$4.66	0.7×	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 7 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-11	$-0.08	$-0.06	+25.0%
2026-02-09	$-0.10	$-0.06	+40.0%
2025-11-25	$-0.13	$-0.11	+15.4%
2025-08-12	$-0.13	$-0.16	-23.1%
2025-05-13	$-0.16	$-0.13	+18.8%
2025-02-12	$-0.17	$-0.14	+17.6%
2024-12-23	$-0.16	$-0.14	+12.5%
2024-08-06	$-0.16

DCF fair valuemodel estimate

Intrinsic value

$1.17

Price

$3.27

Implied downside

-64%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
AVXLAnavex Life Sciences Corp.	$3.27	-4.11%	$303M	—
ABSIAbsci Corporation	$9.46	-0.42%	$1.6B	—
ARVNArvinas, Inc.	$9.01	+1.58%	$581M	—
ATXSAstria Therapeutics, Inc.	$12.58	+0.00%	$718M	—
CTMXCytomX Therapeutics, Inc.	$3.35	-4.01%

Anavex Life Sciences

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

www.anavex.com

Employees: 34
IPO / List date: Aug 2, 2006
HQ: NEW YORK, NY

Held by traders on TradeandTell

No one on the platform currently holds AVXL.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	276,800	$849.8K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Stock splits

Execution date	Ratio
2015-10-07	1-for-4reverse

Recent trades on TradeandTell

No one on the platform has traded AVXL yet.

$AVXL chatter on StockTwits

GenZ@Burt1345m
$AVXL These are the guys that want to take over the BOD
View on StockTwits ↗
Someone@papatrick1h
$AVXL back on coordinated short attack like it was...return to highest high short levels, what was it already...25M shares? we are now at 14M?
View on StockTwits ↗
Aura@ExploringTradesBullish6h
Put ticker JUNS onto your watchlist right now! JUNS has only 770k shares outstanding and only 480k shares public float. Look at what SDOT / YXT / DFNS / AKAN did on similar share numbers recently! JUNS has a similar move coming - Added a big position for a squeeze. $AVXL $SMH $GRRR swing now
View on StockTwits ↗
George@GeorgejjBullish9h
$AVXL AVXL stock should be UP at least 10% today!!! “… Alzheimer’s Disease Program: In March 2026, the Company opened an investigational new drug application (IND) for early Alzheimer’s disease with the FDA, a key step enabling U.S. clinical studies and substantive FDA discussions on the path forward. Two foundational clinical pharmacology studies are now underway under this IND: an absorption, distribution, metabolism and excretion (ADME) study expected to begin in the third calendar quarter of 2026, and a drug-drug interaction (DDI) study where dosing has already started. Both studies are designed to strengthen the regulatory pathway across all blarcamesine indications in parallel with our ongoing early Alzheimer’s disease program. We intend to engage with the FDA on a U.S. clinical development strategy, informed in part by our review of the EMA’s CHMP assessment report….”
View on StockTwits ↗
JJ Hedge@AIIAAIIA_88Bullish9h
$ACIU $PRTA $AVXL Will this one be the winner on the AD/PD field? This field has been a graveyard for so many drug candidates…. I have 3-5-7 year horizon with my position with this one just established.
View on StockTwits ↗
McNibbler@McNibbler9h
$AVXL daily price action is noise. Up 10-15% in a couple weeks and then rug pulled over a day or two. It’s not about the company, it’s about creating volatility to collect premiums. Not unique to Avxl. (We are the market,) is the attitude of MM’s and hedge funds. Nothing to do but pontificate while we wait for a material change.
View on StockTwits ↗
Nobody@Bio_Oko9h
$AVXL point well made: why to replace the entire board? It means monopoly on policy. Absolute power corrupts absolutely.
View on StockTwits ↗
August Steffen@Itinerant10h
$AVXL What is the meaning of this price action today? Do they think that the incumbent board posture is lame? What do you think?
View on StockTwits ↗
Bn69111@Bn6911110h
$AVXL ah yes here is that familiar feeling 🙂
View on StockTwits ↗
ninja@Series4Guy10h
$AVXL THIS⬇️ I know Clint and the legal team read this board!! Dishonest Clint, get rid of him
View on StockTwits ↗
Ken BRIGHT@Tunken10h
$AVXL Anavex Life Sciences Corp. (AVXL) was scheduled to report its third-quarter fiscal 2026 results on August 11, 2026. However, the company disclosed a filing delay with the SEC around that time, extending timelines as it manages prior reporting delinquency issues and compliance plans with Nasdaq.Filing and Compliance ContextQuarterly Period: Fiscal Q3 2026 (ending June 30, 2026).Scheduled Release: August 11, 2026.Filing Status: Delayed, following a previous Form 10-Q late-filing notification for the period ending March 31, 2026.Regulatory Body Rules: Timely periodic reporting via Form 10-Q is monitored under SEC rules and Nasdaq Listing Rule 5250(c)(1).
View on StockTwits ↗
JR Mendez@PartyNaked11h
$AVXL Our choice is between the existing board that has demonstrated unwavering incompetence or a parasitic end-run replacement board with questionable shareholders interest. Vote early and often.
View on StockTwits ↗
JohnnyMoneyBags@jcolespartan13h
$AVXL Please tell me most of you all remember: BLUE HORSESHOE And the results that occured to the company. Possibly the same PLAYBOOK!
View on StockTwits ↗
Trainguy1@Trainguy115h
$AVXL Dear Mr Adams: As an Anavex Life Sciences stockholder, I am aware that PVG is trying to take control of Anavex’s board of directors, but I am not aware of PVG’s overall intentions. Are you planning to develop a presentation that spells out PVG’s plan for Anavex? I view this as a necessary resource for making a decision about which BoD candidates to vote for. Based on the small amount of information I’ve seen, it doesn’t look like any PVG board of director candidate has the expertise or detailed knowledge needed to shepherd Anavex through FDA meetings, clinical trials, NDA development, and all other steps leading to drug approval. Therefore, I assume PVG simply wants to sell Anavex or its assets. Would you please advise if my understanding is correct? If not, when can I expect a presentation to be made available? I look forward to receiving your response.
View on StockTwits ↗
Max@OnlyUp0116h
$AVXL PVG is attempting to orchestrate a backdoor BO. They're attempting to take control or influence the decision making process of Anavex without paying a premium to shareholders. Their only interest is to enrich themselves or they wouldn't waste their time and effort period. I'm not saying the current board and it's two new nominees are the idea solution or they couldn't use a push of some outside influence but PVG is not the answer. They're not even close to the answer. In fact, they are the polar opposite of the answer. They're preying upon your frustration and disappointment. If this was a properly constructed BO than I would be all ears but it's not. You want a return on your investment? There is no way in hell you'll get it with PVG. You'll get pennies on the dollar if that. Just think about what PVG really wants. Do you think for one nanosecond they have shareholders interest as their goal? Absolutely and emphatically NO. They see a golden opportunity to make themselves money.
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.